63 results about "Drug Dependency" patented technology

The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.

The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.

The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.

A vibrational instrument which is therapeutically beneficial in treating the person suffering from afflictions such as headache, sinus congestion and pressure, and withdrawal due to drug dependency includes a member capable of transmitting vibrational waves through the teeth, jaw and sinus tissue for disposal between teeth of the person. A method of treatment is also provided.

The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.

A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or another agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or its other agonist in an amount sufficient to at least partially block the pharmacologic defects of the drug or its other agonist while there is a substantial amount of the drug or other agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or other agonist. In another embodiment, the drug or its other agonist is first administered and the antagonist is self-administered by a subject in a manner which mimics the use of the drug thereby counter-conditioning the drug user to the stimuli associated with the normal administration of the drug. The invention further provides a method of therapeutically treating psychophysiologic diseases and disorders involving neuronal dysregulation. The method additionally provides a pharmacologic composition for the treatment and reduction of drug dependence and which relies upon a combination of an agonist and antagonist.

The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.

The present disclosure is directed to modulators of opiate- and / or NMDA receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and / or management of pain, anxiety, neurodegeneration, drug dependence, coughing, muscular tension, and / or glaucoma and any other condition in which it is beneficial to modulate an opiate- and / or NMDA receptor.

The invention discloses propofol fat emulsion injection and a preparation method thereof. The propofol fat emulsion injection comprises, by weight percent, 1% of propofol, 6-8% of soybean oil, 1.5-2.0% of soybean lecithin, 3-5% of glycerol, 0.1-0.8% of tween-80, 0.05-0.1% of phosphoric acid, appropriate amount of pH regulator and the balance of water for injection, wherein the amount of the pH regulator is enough to regulate pH of the water for injection to 7.5-8.0. The propofol fat emulsion injection improves drug delivery, decreases particle size, and improves uniformity of particle size, and accordingly stability of the injection is improved, pain during injection is lowered, and drug dependency of patients is increased.

Mice in which OCT3 expression is suppressed were successfully constructed by administering antisense against OCT3 gene into the brain. Mice in which OCT3 expression is suppressed display phenotypes related to mental disorders such as anti-depression and anti-anxiety, and therefore the mice can be applied to the screening of therapeutic agents for mental disorders. In addition, substances suppressing the OCT3 expression or function were shown to be in fact effective as therapeutic agents for depression and anxiety neuroses.

The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.

The invention relates to an irinotecan hydrochloride injection consisting of irinotecan hydrochloride (15-25g / L), sorbierite (17.5-22.5g / L), and the balance of phosphoric acid and injection water, wherein the phosphoric acid adjusts the pH of the injection to 3.0-3.8. The invention also relates to a preparation method of the irinotecan hydrochloride injection. Compared with the prior art, the irinotecan hydrochloride injection disclosed by the invention has the following beneficial effects: (1) the untoward effect is reduced; as shown in an animal test, the irinotecan hydrochloride injection disclosed by the invention can greatly reduce the untoward effect of delayed-onset diarrhea caused by irinotecan, which has an active promotion effect on the drug dependency and treatment effect of cancer patients; (2) the stability is high, as shown in an acceleration test, the character, acidity, solution clarity and color, insoluble particles, visible foreign matters, moisture, related substance and content of the irinotecan hydrochloride injection meet the regulations; and (3) the preparation method is simple and is favorable to the industrial mass production.

A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.

The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.

The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and / or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and / or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and / or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.

A remedy for drug dependence in which the active ingredient is an opioid kappa receptor agonist in which the typical compound is represented by the following formula. An opioid kappa receptor agonist in accordance with the present invention is different from a conventional symptomatic treatment manner for the drug dependence. The opioid kappa receptor agonist in accordance with the present invention is a promising remedy for drug dependence with little adverse effects which affects expression mechanism of a reward effect so as to inhibit development both psychic dependence and physical dependence.

The present invention relates to a Chinese medicine composition for treating partial eclipse and anorexia of children, a preparation and a manufacturing method thereof. The Chinese medicine composition belongs to the field of Chinese medicine science and comprises the raw medicinal herbs by weight: 1-10 parts of bighead atractylodes rhizome, 10-20 parts of cardamom, 10-15 parts of finger citron, 2-3 parts of clove, 2-8 parts of citrus reticulate blanco, 3-8 parts of amomum villosum, 10-30 parts of radish seeds, 10-15 parts of agastache rugosa and 2-10 parts of banksia rose. The Chinese medicine composition of the invention has excellent curative effect for treating partial eclipse and anorexia of children. Furthermore the optimal preparation form of the invention is external-used powder and has the advantages of simple preparing method and convenient using of directly pasting. The Chinese medicine composition of the invention has no toxic or side effect or drug dependency, and can be used for a long time.

Substituted oxazole derivatives corresponding to formula I:a method for producing such compounds, pharmaceutical compositions containing such compounds, and the use of such compounds to treat pain, depression, urinary incontinence, diarrhoea, pruritus, alcohol and drug misuse, drug dependency, lethargy and / or anxiety.

The invention discloses propofol fat emulsion injection and a preparation method thereof. The propofol fat emulsion injection comprises, by weight percent, 1% of propofol, 6-8% of soybean oil, 1.5-2.0% of soybean lecithin, 3-5% of glycerol, 0.1-0.8% of tween-80, 0.05-0.1% of phosphoric acid, appropriate amount of pH regulator and the balance of water for injection, wherein the amount of the pH regulator is enough to regulate pH of the water for injection to 7.5-8.0. The propofol fat emulsion injection improves drug delivery, decreases particle size, and improves uniformity of particle size, and accordingly stability of the injection is improved, pain during injection is lowered, and drug dependency of patients is increased.

A vibrational instrument which is therapeutically beneficial in treating the person suffering from afflictions such as headache, sinus congestion and pressure, and withdrawal due to drug dependency includes a member capable of transmitting vibrational waves through the teeth, jaw and sinus tissue for disposal between teeth of the person. A method of treatment is also provided.

The invention relates to the fields of medicines and pharmacology, in particular to a medicine for treating postherpetic neuralgia and a preparation method of the medicine. On the basis of the theory of traditional Chinese medicine and the latest pharmaceutical research achievement and through the utilization of modern technological means, the medicine is prepared into an oral preparation, preferably into capsules, tablets and granules, from radix dipsaci, herba polygoni perfoliati, panax notoginseng, garlic, rhizoma ligustici wallichii, rhizoma curcumae longae, katsumade galangal seed, radix aucklandiae, diverse wormwood herb, amaranthus viridis, flos carthami, fructus amomi, lalang grass rhizome, sweet broomwort herb, folium hibisci, rhizoma paridis and the like. Pharmacodynamic experiment researches show that the medicine provided by the invention has an ideal inhibitory effect on PHN, and the medicine provided by the invention is convenient to use, good in safety and free from drug dependency; the medicine, which is completely prepared from natural medicinal herbs, is free from any chemical additives, and the medicine, when taken for a long time, is safe and reliable; the tolerance and the compliance of patients can be improved to a great extent, so that a novel optional scheme is provided for the long-term treatment of the patients with the PHN; and the medicine can meet current clinical demands.

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

The invention provides a traditional Chinese medicine composition for treating light-headedness, and relates to the technical field of Chinese herbal medicines. The formula of the traditional Chinese medicine composition comprises 20-50 parts of glossy privet fruit, 20-50 parts of mulberry fruit, 5-15 parts of ligusticum wallichii, 10-30 parts of herba ecliptae and 10-30 parts of motherwort in a weight ratio. The glossy privet fruit, the mulberry fruit, the ligusticum wallichii, the herba ecliptae and the motherwort are added to water in proportion and decocted with water and a patient can take the decoction which is cooled to warm. The traditional Chinese medicine composition can be used for effectively treating the light-headedness and is capable of avoiding various side effects and drug dependency often caused by the long-term taking of medicines for treating illness; the used materials are common food in daily life and low in cost; the disease is treated when people enjoy delicious food; and by taking the traditional Chinese medicine composition, the pains caused by injection, medicine taking even operation can be avoided.

The invention provides an anti-inflammatory and antibacterial pharmaceutical composition. The pharmaceutical composition comprises the following active ingredients in parts by weight: 130-190 parts ofpomegranate rind, 120-160 parts of scutellaria baicalensis, 100-140 parts of sanguisorba officinalis and 100-140 parts of phellodendron amurense. In addition, the invention also provides a preparation method of the anti-inflammatory and antibacterial pharmaceutical composition. The anti-inflammatory and antibacterial pharmaceutical composition is a pure traditional Chinese medicine preparation, has good anti-inflammatory and antibacterial effects, is small in dosage, convenient to take, wide in application range, definite in curative effect, safe and reliable, free of relapse in curing, freeof drug property dependence and free of side effects, and can achieve the effect of treating both symptoms and root causes.

The invention relates to a nasal drop and a preparation method thereof. The nasal drop is prepared from the following raw material medicines in parts by weight: 1-2mL of a chlorpheniramine maleate injection which comprises 10-20mg of chlorpheniramine maleate, 1-3mL of a moroxydine hydrochloride injection which comprises 50-150mg of moroxydine hydrochloride, 0.1-0.5mL of a hydrochloric acid racanisodamine injection which comprises 1-5mg of hydrochloric acid racanisodamine, and 3-6mL of a radix bupleuri extract. The preparation method specifically comprises the following steps of: mixing the raw material medicines according to the ratio, and filling into a nasal drop container. The nasal drop is safe in medicinal formula, small in toxic and side effect, reasonable in matching of traditional Chinese medicines and western medicines, applicable to infants, free of hormone and free of drug dependency.

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

The invention discloses a drug for preventing respiratory infectious diseases. The drug comprises the following components in parts by weight: 4 to 15 parts of tuber of dwarf lilyturf, 5 to 16 parts of cortex lycii, 5 to 15 parts of bighead atractylodes rhizome, 2 to 12 parts of dragon's blood, 5 to 15 parts of safflower, 2 to 10 parts of honeysuckle flower, 2 to 10 parts of fructus forsythiae, 2 to 13 parts of isatis root, 1 to 6 parts of radix bupleuri, 2 to 10 parts of radix scutellariae, 6 to 12 parts of apricot kernel, 10 to 18 parts of radix codonopsis, and 2 to 13 parts of imperata rhizome. The formula of the drug is reasonable. The drug has a prominent preventive effect on respiratory infectious diseases, and the effect is long lasting. Moreover, the drug does not have any side or toxic effect. The drug dependency is not generated even if the patients take the drug for a long term.